首页|对药物临床试验老年受试者依从性管理的建议

对药物临床试验老年受试者依从性管理的建议

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
药物临床试验是评估新药安全性、有效性,推动医学进步,提供创新治疗方法不可或缺的关键步骤;在中国老龄化人口增加的趋势下,提升临床试验老年受试者的依从性至关重要.为确保研究结果更具代表性和适用性,建议采取以下措施:首先,制定个性化支持计划和多元化的依从性监测方法;其次,根据老年人的生活方式和需求,调整试验设计以提升参与的舒适度和便捷性;此外,建立社会支持系统以提供更广泛的支持;最后,通过加强研究团队的培训,提高对老年患者的关怀水平,激发其积极性和合作度.这些举措有助于减小药物临床试验的选择性和信息偏倚,为改善医疗护理和推动医学科学的发展提供可靠的研究基础.通过科学、伦理和规范的试验设计和实施,可以更好地评估药物的效果,为患者提供更好的医疗选择.
Recommendations for compliance management of elderly participants in drug clinical trials
Clinical drug trials are crucial steps in assessing the safety and efficacy of new medications,driving medical advancements,and providing essential innovation in treatment methods.With the increasing trend of aging populations in China,enhancing the compliance of elderly participants in clinical trials is of paramount importance.To ensure more representative and applicable research outcomes,the following measures are recommended:firstly,establish personalized support plans and diverse compliance monitoring methods.Secondly,adjust trial designs based on the lifestyles and needs of older individuals to enhance participation comfort and convenience.Furthermore,establish social support systems to provide broader assistance.Finally,strengthen the training of research teams to elevate the level of care for elderly patients and stimulate their enthusiasm and cooperation.These initiatives contribute to reducing selection and information biases,laying a reliable research foundation for improving healthcare and driving advancements in medical science.Through scientifically,ethically,and rigorously designed and implemented trials,a better assessment of the effectiveness of medications can be achieved,offering improved medical choices for patients.

clinical drug trialsolder subjectscomplianceinformation biasresearch results

胡薏慧、杨晓燕、汤洁、彭朋、元唯安

展开 >

上海中医药大学附属曙光医院临床研究中心,上海 201203

上海中医药大学附属曙光医院中药房,上海 201203

药物临床试验 老年受试者 依从性 信息偏倚 研究结果

上海市中医药三年行动计划上海市"科技创新行动计划"生物医药科技支撑专项上海市教委协同创新中心:中西医结合中成药临床评价平台项目上海市慢性筋骨病临床医学研究中心项目上海市科委应急科技攻关计划(第三批)(2022)上海市申康中心示范性研究型病房建设项目上海市申康中心医企融合创新协同专项

ZY2021-2023-021120S21902100Al-U21-205-010320MC192060022YJ1900505SHDC2022CRW010SHDC2022CRT018

2024

10.7501/j.issn.1674-6376.2024.03.001

药物评价研究
天津药物研究院 中国药学会

药物评价研究

CSTPCD北大核心
影响因子：1.199
ISSN：1674-6376
年,卷(期)：2024.47(3)
  • 34